Skip to content

LB Pharmaceuticals

US · LBRX #3180 by market cap Listed 2025
38.85 -1.19 -2.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 39.53 -1.27%
After-hours 38.85 0.00%
49.4827.0238.852026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LBRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +64.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 19.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 38.3x Better than 14%
P/E vs own 5-yr range 99th pctl Better than 4%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Return on equity -24.4% Better than 15%
Return on invested capital -27.2% Better than 11%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -18.4% Better than 33%
6-month return 38.2% Better than 92%
12-month return (ex latest month) 152.6% Better than 98%
Distance below 52-week high 22.5% Better than 55%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 41.4x Better than 99%
Debt to assets 1.1% Better than 92%
Interest coverage -0.3x Better than 23%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 69.6% Better than 76%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.67%
1M -5.24%
3M -17.74%
6M +38.60%
YTD +74.53%
1Y +146.04%

Key statistics

Price & volume

Prev close
40.04
Open
39.53
Day range
38.57 - 40.67
Avg price
38.97
Volume
303.06K
Turnover
11.81M
Amplitude
5.25%
52-week range
15.55 - 50.16

Valuation

P/E
-39.01
P/E (TTM)
38.31
P/B
3.01
EPS
-1.00
Net profit
-32.23M
Net assets
417.65M

Share structure

Market cap
1.26B
Float cap
1.03B
Shares out
32.36M
Float shares
26.46M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2025-09-11
52-week range 67% of range
15.55 50.16

22.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+1.35M net over the window

Short interest

Shares short
6.20M
As of
2026-10-30

Frequently asked questions

What is the current stock price of LB Pharmaceuticals (LBRX)?

LB Pharmaceuticals last traded at 38.85. This page shows a periodic quote snapshot. Check the displayed quote time.

What is LB Pharmaceuticals's market cap?

About 1.26B.

What is the P/E ratio of LB Pharmaceuticals?

The trailing twelve-month P/E is 38.31. The Valuation tab shows it against the stock's own five-year range.

Does LB Pharmaceuticals pay a dividend?

LB Pharmaceuticals does not currently pay a regular dividend.

Is LB Pharmaceuticals a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 65.88, which implies 69.6% upside from the current price. This is not investment advice.

What is LB Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates LB Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

LB Pharmaceuticals discussion 0 comments

Add a comment